The World’s First Clinical Trial on Therapeutic Indication of Recombinant Botulinum Toxin Type A (YY001-002) Receives CDE approval

The World’s First Clinical Trial on Therapeutic Indication of Recombinant Botulinum Toxin Type A (YY001-002) Receives CDE approval

GUANGZHOU, July 5th, 2024 -- MingMed Biotechnology Co., Ltd today announced that its subsidiary, Cla...